Product
Lipo-MERIT
1 clinical trial
1 indication
Indication
MelanomaClinical trial
Clinical First-in-human Dose Escalation Study Evaluating the Safety and Tolerability of Intravenous Administration of a Tetravalent RNA-lipoplex Cancer Vaccine Targeting the Tumor-associated Antigens NY-ESO-1, Tyrosinase, MAGE-A3, and TPTE in Patients With Advanced MelanomaStatus: Completed, Estimated PCD: 2023-06-20